Solid Biosciences Inc.
SLDB
$6.83
-$0.01-0.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 127.35M | 115.30M | 95.44M | 95.44M | 95.44M |
| Gross Profit | -127.35M | -115.30M | -95.44M | -95.44M | -95.44M |
| SG&A Expenses | 34.45M | 33.30M | 30.98M | 29.54M | 28.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 142.92M | 129.73M | 112.10M | 100.03M | 99.15M |
| Operating Income | -142.92M | -129.73M | -112.10M | -100.03M | -99.15M |
| Income Before Tax | -139.68M | -124.70M | -102.44M | -90.69M | -90.25M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -139.68 | -124.70 | -102.44 | -90.69 | -90.25 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -139.68M | -124.70M | -102.44M | -90.69M | -90.25M |
| EBIT | -142.92M | -129.73M | -112.10M | -100.03M | -99.15M |
| EBITDA | -140.38M | -127.27M | -109.92M | -97.67M | -96.92M |
| EPS Basic | -2.99 | -3.04 | -3.04 | -3.30 | -3.94 |
| Normalized Basic EPS | -1.87 | -1.90 | -1.90 | -2.06 | -2.46 |
| EPS Diluted | -2.99 | -3.04 | -3.04 | -3.30 | -3.94 |
| Normalized Diluted EPS | -1.87 | -1.90 | -1.90 | -2.06 | -2.46 |
| Average Basic Shares Outstanding | 191.43M | 163.24M | 140.77M | 119.38M | 98.11M |
| Average Diluted Shares Outstanding | 191.43M | 163.24M | 140.77M | 119.38M | 98.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |